ZIL-O - Indications: bacterial infections
To reduce the development of drug-resistant bacteria and maintain the effectiveness of (ofloxacin tablets) Tablets and other antibacterial drugs, (ofloxacin tablets) Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.(ofloxacin tablets) Tablets are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae or Streptococcus pneumoniae. Community-acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae. Nongonococcal urethritis and cervicitis due to Chlamydia trachomatis. Mixed Infections of the urethra and cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae. Acute pelvic inflammatory disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae. NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus*, or Pseudomonas aeruginosa*.Prostatitis due to Escherichia coli.
Indications: Genito urinary, respiratory, gastro intestinal.
skin and soft tissue infections.
Typhoid fever, Multi drug resistant tuberculosis.
Acute and sub-acute eye and ear infections.
Ofloxacin is a fluoroquinolone antibiotic considered to be a second-generation fluoroquinolone. Floxin (branded version) had been discontinued by the manufacturer, in the United States, effective June 18, 2009, though generic equivalents continue to be available.
Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin. When levofloxacin disks were not available in early clinical trials, a 5-pg Floxin (ofloxacin –floxacin) disk was substituted. The U.S. Food and Drug Administration (FDA) medical reviewers considered the two drugs to be one and the same and hence interchangeable.
Like other quinolones, ofloxacin has been associated with a significant number of serious adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); such reactions may manifest long after therapy had been completed, and, in severe cases, may result in life-long disabilities. Ofloxacin has also been associated with severe psychiatric adverse reactions.
Hepatotoxicity has also been reported with the use of ofloxacin. Case reports of hepatitis have been published for the older fluoroquinolones including ciprofloxacin, ofloxacin, and norfloxacin.